Disposable field effect transistors (FET) biosensors (bio-FET) based on carbon nanotubes were fabricated for detection of domoic acid (DA), which belongs to the group of biotoxins associated with the amnesic shellfish poisoning. The analytical results obtained with the bio-FET were compared with those obtained with a traditional methodology (enzyme-linked immunosorbent assay) in order to validate the bio-FET for DA detection. Standard solutions of DA with concentrations between 10 and 500 ng L−1 were tested in order to construct the calibration curve, where five bio-FET were used for reproducibility estimation and two analytical measurements were performed for each bio-FET for repeatability estimation. Ten spiked artificial seawater samples were used to validate the bio-FET. The obtained reproducibility (0.52–1.43%), repeatability (0.57–1.27%), limit of detection (10 ng L−1) and recovery range (92.3–100.3%) reveal an adequate analytical performance of the bio-FET for the detection of DA in environmental samples such as seawater samples.
This paper describes an untargeted NMR metabolomics study to identify potential intracellular donor-dependent and donor-independent metabolic markers of proliferation and osteogenic differentiation of human adipose mesenchymal stem cells (hAMSCs). The hAMSCs of two donors with distinct proliferating/osteogenic characteristics were fully characterized regarding their polar endometabolome during proliferation and osteogenesis. An 18-metabolites signature (including changes in alanine, aspartate, proline, tyrosine, ATP, and ADP, among others) was suggested to be potentially descriptive of cell proliferation, independently of the donor. In addition, a set of 11 metabolites was proposed to compose a possible donor-independent signature of osteogenesis, mostly involving changes in taurine, glutathione, methylguanidine, adenosine, inosine, uridine, and creatine/phosphocreatine, choline/phosphocholine and ethanolamine/phosphocholine ratios. The proposed signatures were validated for a third donor, although they require further validation in a larger donor cohort. We believe that this proof of concept paves the way to exploit metabolic markers to monitor (and potentially predict) cell proliferation and the osteogenic ability of different donors.